Tenax Therapeutics, Inc.
TENX
Price:
$3.77
Market Cap:
$12.85M
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax The...[Read more]
Industry
Biotechnology
IPO Date
1994-04-04
Stock Exchange
NASDAQ
Ticker
TENX
The ROE as of September 2024 (TTM) for Tenax Therapeutics, Inc. (TENX) is -48.90%
According to Tenax Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -48.90%. This represents a change of 191.83% compared to the average of -16.76% of the last 4 quarters.
Tenax Therapeutics, Inc. (TENX) Historical ROE (quarterly & annually)
How has TENX ROE performed in the past?
The mean historical ROE of Tenax Therapeutics, Inc. over the last ten years is -250.19%. The current -48.90% ROE has changed -80.45% with respect to the historical average. Over the past ten years (40 quarters), TENX's ROE was at its highest in in the March 2024 quarter at 30.56%. The ROE was at its lowest in in the March 2021 quarter at -767.14%.
Average
-250.19%
Median
-156.47%
Minimum
-771.09%
Maximum
-23.31%
Tenax Therapeutics, Inc. (TENX) ROE by Quarter and Year
Discovering the peaks and valleys of Tenax Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 999.54%
Maximum Annual ROE = -23.31%
Minimum Annual Increase = -104.45%
Minimum Annual ROE = -771.09%
| Year | ROE | Change |
|---|---|---|
| 2023 | -95.22% | -87.13% |
| 2022 | -739.79% | -4.06% |
| 2021 | -771.09% | 261.33% |
| 2020 | -213.41% | -4.09% |
| 2019 | -222.51% | 288.99% |
| 2018 | -57.20% | -42.52% |
| 2017 | -99.53% | -61.16% |
| 2016 | -256.25% | 999.54% |
| 2015 | -23.31% | -1.15% |
| 2015 | -23.58% | -104.45% |
Tenax Therapeutics, Inc. (TENX) Average ROE
How has TENX ROE performed in the past?
The current ROE of Tenax Therapeutics, Inc. (TENX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-535.36%
5-year avg
-408.40%
10-year avg
-250.19%
Tenax Therapeutics, Inc. (TENX) ROE vs. Peers
How is TENX’s ROE compared to its peers?
Tenax Therapeutics, Inc.’s ROE is greater than Allarity Therapeutics, Inc. (-704.78%), greater than NeuroBo Pharmaceuticals, Inc. (-154.04%), greater than Hillstream BioPharma, Inc. (-47249.59%), greater than Virax Biolabs Group Limited (-115.10%), greater than Quoin Pharmaceuticals, Ltd. (-112.11%), greater than Blue Water Vaccines, Inc. (-111.44%), greater than PaxMedica, Inc. Common Stock (-1151.68%), greater than Revelation Biosciences, Inc. (-243.91%), greater than ZyVersa Therapeutics, Inc. (-172.51%), greater than Sonnet BioTherapeutics Holdings, Inc. (-398.33%), greater than Navidea Biopharmaceuticals, Inc. (-63.06%), greater than Altamira Therapeutics Ltd. (-233.96%), greater than Windtree Therapeutics, Inc. (-123.93%), greater than Dermata Therapeutics, Inc. (-197.44%), greater than Ensysce Biosciences, Inc. (-705.90%), less than Panbela Therapeutics, Inc. (545.45%), less than Baudax Bio, Inc. (54.54%), greater than Aditxt, Inc. (-607.01%), less than Unicycive Therapeutics, Inc. (294.74%),
| Company | ROE | Market cap |
|---|---|---|
| -704.78% | $4.75M | |
| -154.04% | $30.52M | |
| -47249.59% | $4.17M | |
| -115.10% | $12.37M | |
| -112.11% | $2.45M | |
| -111.44% | $3.41M | |
| -1151.68% | $976.23K | |
| -243.91% | $1.50M | |
| -172.51% | $2.55M | |
| -398.33% | $4.50M | |
| -63.06% | $100.08K | |
| -233.96% | $1.68M | |
| -123.93% | $1.85M | |
| -197.44% | $2.80M | |
| -705.90% | $3.88M | |
| 545.45% | $1.63M | |
| 54.54% | $8.13M | |
| -607.01% | $2.47M | |
| 294.74% | $35.69M |
Build a custom stock screener for Tenax Therapeutics, Inc. (TENX) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Tenax Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Tenax Therapeutics, Inc. (TENX) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Tenax Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Tenax Therapeutics, Inc.'s ROE?
How is the ROE calculated for Tenax Therapeutics, Inc. (TENX)?
What is the highest ROE for Tenax Therapeutics, Inc. (TENX)?
What is the 3-year average ROE for Tenax Therapeutics, Inc. (TENX)?
What is the 5-year average ROE for Tenax Therapeutics, Inc. (TENX)?
How does the current ROE for Tenax Therapeutics, Inc. (TENX) compare to its historical average?